Pfizer is voluntarily recalling two lots of eletriptan hydrobromide (Relpax) 40 mg tablets to the patient level. Pfizer initiated the recall because the product lots may not meet the company’s in-house microbiological specification for the potential presence of genus Pseudomonas and Burkholderia.
The lot numbers are AR5407 and CD4565.
Eletriptan is indicated for the acute treatment of migraine.